Tel:+86-027-59403931 Ext 8009 
Email: wwqin@oryzogen.com
Contact Us
Inquiry Now 
Wuhan Healthgen Biotechnology Corp. (Healthgen Biotech) is a public listed company founded in 2006(Stock code:688765). Healthgen Biotech specializes in molecular pharmaceutical research and development. Its commission is to use a state-of-art technology, rice endosperm cell specific expression platform (Oryzᴴⁱᴱˣᵖ), with high capacity to express proteins or small peptides in the rice grain, to develop the plant-made pharmaceuticals (PMP). The PMP provides a new approach for production of biopharmaceuticals.
Biopharmaceutical Pipeline
The pharmaceutical pipeline below is updated as of August 2026.
As an alternative to human plasma-derived albumin, Olbumin® Recombinant Human Albumin Injection (Oryza Sativa) resolves two core pain points: constrained plasma raw material supply and infectious virus transmission risks associated with plasma preparations, offering enhanced safety and stability for global clinical application.
Learn More
Raw Materials For Life Science
Healthgen Biotech’s state-of-the-art technology obtained a number of patents in China and international-wide. Utilizing Oryzᴴⁱᴱˣᵖ platform, Healthgen Biotech have achievements in developing and commercializing a series of products, including Recombinant Human Serum Albumin (OsrHSA), Recombinant Human Transferrin(OsrhTF), Recombinant Human Fibronectin(OsrhFN) and growth factors. Meanwhile, Healthgen Biotech can provide customized protein or peptides expression services.
Rice-derived recombinant proteins are widely adopted as cell culture supplements and pharmaceutical excipients in biopharmaceutical manufacturing. Additionally, they can be applied as raw materials for in vitro diagnostics, medical supplies, and personal care formulations.
